Pharmacology

Glenmark Pharmaceuticals has announced that GRC 27864 is entering human trials.  GRC 27864  targets Microsomal Prostaglandin E synthase-1 (mPGES-1) as a therapeutic target in pain management. Selective mPGES-1 inhibitors are expected to inhibit increased prostaglandin E2 (PGE2) production in the disease state without affecting other prostanoid metabolites and, consequently, may be devoid of the GI (gastrointestinal) and cardiovascular side effects seen with NSAIDs and COX-2 inhibitors, respectively.
Alzheimer’s disease is a debilitating neurodegenerative disease and the most common form of dementia. Symptoms include irritability, confusion, mood swings, language difficulties and memory loss. Cognitive dysfunction becomes more pronounced as the disease progresses, leading to the loss of bodily functions and eventually death.

Erectile dysfunction is common among older men with cardiovascular risk factors where cholesterol-lowering statins are frequently prescribed.

Matching curves have suggested a negative association between statin therapy and testosterone levels, leading to concerns about the effects of these medications on the quality of erection. Not so, according to a meta-analysis of previous studies on erectile dysfunction and statins. Instead, the authors find that statins are associated with a significant improvement in erectile function, a fact researchers hope will encourage men who need statins to reduce their risk of heart attack to take them. 


<!--[if gte mso 9]> <![endif]-->

The Food and Drug Administration announced Thursday that a Pennsylvania-based company is voluntarily recalling several products marketed as dietary supplements for “male enhancement” after the agency says it found they contained active drugs.

Nova Products, Inc., an adult products wholesaler, will recall packs of African Black Ant, Black Ant, XZen Gold, ZXen Platinum, XZen 1200, XZone Gold, and XZone 1200, according to an FDA press release.

Patients with terminal forms of leukemia and lymphoma who have run out of treatment options could still aid science -  a Phase 1 trial into a new class of BTK (Bruton's Tyrosine Kinase) inhibiting drugs at Derriford Hospital in Plymouth.

If it works, the new drug will improve a patients' life expectancy and quality of life by putting an end to chemotherapy with no side effects. 


People who smoke high-potency cannabis end up getting higher doses of THC even if they might reduce the amount they puff and inhale to compensate for the higher strength Result: they still take in more THC than smokers of lower potency cannabis.


Between 2001 and 2010, there were dramatic increases in Emergency Room prescriptions of opioid analgesics, such as Percocet, Vicodin, oxycodone and Dilaudid.

No surprise there, America is increasingly over-medicated, be it on supplements, homeopathy or legitimate treatments.

And it's going to get worse. If current trends under the Affordable Care Act persist, fewer and fewer doctors will accept government plans, and that means even more people will go to the ER, at far higher cost. ER doctors have to treat a lot of people and 'pain' is an entirely subjective claim, one of the last vestiges remaining of symptom-based diagnosis in the field.


While there's no genetic basis for anorexia nervosa, psychiatrists say there may be a chemical treatment - oxytocin, the 'love hormone'.  


A team of researchers led by Mayland Chang and Shahriar Mobashery have discovered a new class of antibiotics to fight bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria that threaten public health. 


Glioblastoma is the most common primary malignant adult brain tumor and, despite treatment advances in recent years, the average survival of patients enrolled in clinical trials is less than 16 months.

Few patients live beyond five years.

Glioblastoma
tumors are characterized by angiogenesis — the formation of new blood vessels that support tumor growth stimulated by the GBM-produced vascular endothelial growth factor A (VEGF-A).

Bevacizumab is a monoclonal antibody that targets VEGF-A production to block the growth of tumor-derived blood vessels.